News

Press Releases:

August 10, 2010
Pathway Therapeutics Completes $4.5 Million Financing for Novel PI3K Inhibitor Portfolio

October 9, 2009
Pathway Therapeutics Completes $3 Million Financing for Cancer Programs and appoints Dr. Julie Cherrington as Chief Executive Officer

December 4, 2008
Pathway Therapeutics, a New Zealand drug development company, is the first recipient of funding from the Trans Tasman Commercialisation Fund (TTCF)

June 18, 2008
$10million for Pathway cancer drugs